Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a repurchase of 56,500 H shares on 03 June 2026, executed on the Hong Kong Stock Exchange at prices ranging from HKD 19.16 to HKD 20.20. The transaction amounted to HKD 1.11 million, implying a volume-weighted average price of HKD 19.68 per share.

Following the buyback, issued shares excluding treasury stock decreased by 0.0169% to 325.58 million, while treasury shares increased to 10.77 million. Total issued shares remained unchanged at 336.35 million.

Under the general mandate approved on 13 May 2026, the company is authorised to repurchase up to 32.72 million shares. Cumulative buybacks since the mandate’s approval now stand at 1.62 million shares, representing 0.485% of the issued share base as of the mandate date.

A 30-day moratorium on new share issues, sales, or transfers of treasury shares is in effect until 03 July 2026, in accordance with Main Board Rule 10.06(3)(a).